161O VIOLETTE: Randomised phase II study of olaparib (ola) + ceralasertib (cer) or adavosertib (ada) vs ola alone in patients (pts) with metastatic triple-negative breast cancer (mTNBC)

Andrew Tutt, Zbigniew Nowecki, R. Szoszkiewicz, S-A. Im, H-T. Arkenau, Anne Armstrong, William Jacot, Jae Hyoung Kim, M. Webster, Judith Balmañà, Suzette Delaloge, Natalia Lukashchuk, R.I. Odegbami, Ed Casson, A.B. Loembe, Moritz Wolfgang Drachsler, Emma Dean, Kevin Punie